Patients Discontinuing Weight-Loss Jabs Regain Weight Far More Rapidly Compared to Those on Conventional Diets

Fresh analysis indicates that patients who come off new slimming jabs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who halt conventional lifestyle plans.

Findings released in a leading medical journal points out that while overweight people frequently drop substantial amounts of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.

"Users using such medications must be aware of the potential of rapid weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.

This pace of recovery suggests a return to original mass in about one and a half years.

Comparing Treatments

The study, which looked at dozens of studies involving thousands of patients, compared the results of the injectable medications with conventional dieting.

The team note that people who lose weight through dieting typically have a less rapid weight regain—around 0.1 kg a month—post-intervention.

Understanding the Quick Regain

Nutrition scientists propose the mode of action of the drugs is key to understanding the amplified weight return.

The injections copy a natural hormone called glucagon-like peptide-1, which controls appetite.

"Sustained high doses of GLP-1 levels far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating a significant risk."

An Ongoing Issue?

The NHS suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.

Many experts argue that, considering the likelihood of relapse, the treatment should be considered life-long.

This opinion is supported by pharmaceutical companies, who state that the results "emphasize the long-term nature of obesity," akin to managing conditions like diabetes.

User Experiences

Users who have discontinued the jabs report a intense return of appetite.

"It felt as if a trigger activating and you become ravenous," said a patient.

This difficulty is compounded if patients have not established lasting dietary or behavioural modifications during therapy.

Significant Interest

Figures show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.

• Use is more common among females compared to men.
• The 40s and 50s demographic shows the highest level of interest.
• Many obtain the medications through private prescriptions rather than public health services.

Finally, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and long-term success hinges on combined lifestyle support.